SNGX is heading for a new break out which will but it in a big gap area. Watch 2.48 then 2.54 after will talk at 3.50.Company has over 30 million in non dilutive funding and is waiting on another contract that will give them more funding.Randal Kirk of Intrexon has taken a large stake in them.This bio is bigtime under valued.Gevo oh well enjoy the dead cat before the next big drop into a major dilution share offer.
Lets see; SNGX Chair / P / CEO, Chris Schaber with a diploma mill PhD,
ex DSCO COO (NOW THERES a winning pedigree ! wasnt Schaber part of that truly impressive performance of DSCO from $120 to $22 across a couple weeks ? yeah thats it , fired for that black eye. Seems "Chris Schaber Ph.D. is the guy responsible for all of DSCO's mess. Having had the opportunity of an audience with him some months ago I came to see him as a flawed person, someone threatened by anyone smater than he or anyone who had differing opinions, very problematic for a young company " )
had to FORK OVER 9% , 1M shares of SNGX to Kirk/ XON in order to be their clinical arm and minor access to a 'discovery platform' for some cast off compound
an OTCBB with 8 or so phase 1 sky pies in the oven from cancer to bio weapons
NOTHING near the funds you claim.
All set and ready to go ... well, at least as soon as they find em (1) Vice President and Chief Medical Officer and (1) Clinical Project Manager/Director
Never mind the SNGX chart that SCREAMS reversal after a few manufactured days up.
What the heII penny pumper site do you work for? what preposterous outfit are you shilling for ? They are feeding you dreck dude. thanks for the warning to stay the heII away from the soligenix pump thats just about to blow a gasket
no wonder you clowns did so bad with the scam gevo.You guys can't do DD. Kirk owns 31.9% .Have a look at the SEC filings and guess you see they do have the funding i said they had.Gevo only wishes they could get such huge non dilutive funding.Good news is the next contract is coming.Sngx is heading north baby!
On Sept. 25, 2013, Soligenix, Inc. (OTC BB:SNGX) announced that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).
The NIAID contract is awarded for the advanced preclinical development of OrbeShield™ (oral beclomethasone 17,21-dipropionate or oral BDP) as a biodefense medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
This is a contract for three years which contains a one year base period, with two contract options that would extend the contract an additional year each. The total award will support the development activities necessary to evaluate OrbeShield™ as a potential MCM to treat GI ARS.
This is the second government contract Soligenix secured within one week. Last week, Soligenix was awarded a $26.3 million contract by the US Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA). Both contracts are awarded for the advanced preclinical and manufacturing development of OrbeShield™ as a biodefense medical countermeasures (MCMs) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).